TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese
Brief Summary: To study if incisional vacuum-assisted closure can decrease the risk of infection in cesarean section incisions in the obese compared with standard sterile dressing.


Options:
A: Arm Label: High Risk - Prevena Care; Type: EXPERIMENTAL; Interventions: Device: Prevena Care | Arm Label: High Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Arm Label: Low Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Intervention Type: DEVICE; Name: Prevena Care; Assigned to Arm(s): High Risk - Prevena Care | Intervention Type: DEVICE; Name: Dry gauze dressing care; Assigned to Arm(s): High Risk - Dry Gauze Dressing Care, Low Risk - Dry Gauze Dressing Care
B: Arm Label: Vacuum assisted closure; Type: EXPERIMENTAL; Interventions: Procedure: vacuum assisted closure | Arm Label: Axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary dissection | Intervention Type: PROCEDURE; Name: vacuum assisted closure; Assigned to Arm(s): Vacuum assisted closure | Intervention Type: PROCEDURE; Name: Axillary dissection; Assigned to Arm(s): Axillary dissection
C: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy
D: Arm Label: Vacuum-assisted closure (VAC); Type: EXPERIMENTAL; Interventions: Device: Vacuum-assisted closure | Arm Label: Standard sterile dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard sterile dressing | Intervention Type: DEVICE; Name: Vacuum-assisted closure; Assigned to Arm(s): Vacuum-assisted closure (VAC) | Intervention Type: DEVICE; Name: Standard sterile dressing; Assigned to Arm(s): Standard sterile dressing

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese
Brief Summary: To study if incisional vacuum-assisted closure can decrease the risk of infection in cesarean section incisions in the obese compared with standard sterile dressing.


Options:
A: Arm Label: Vacuum Assisted Closure®; Type: EXPERIMENTAL; Interventions: Device: Vacuum Assisted Closure® | Arm Label: Standard conventional wound therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard conventional wound therapy | Intervention Type: DEVICE; Name: Vacuum Assisted Closure®; Assigned to Arm(s): Vacuum Assisted Closure® | Intervention Type: OTHER; Name: Standard conventional wound therapy; Assigned to Arm(s): Standard conventional wound therapy
B: Arm Label: Standard Dressing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Postoperative NPWT dressing; Type: EXPERIMENTAL; Interventions: Device: Postoperative Negative Pressure Wound Therapy KCI NANOVA | Intervention Type: DEVICE; Name: Postoperative Negative Pressure Wound Therapy KCI NANOVA; Assigned to Arm(s): Postoperative NPWT dressing
C: Arm Label: Simple dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Smith & Nephew PICO Negative wound pressure versus standard dresing, Device: PREVENA Negative pressure wound versus standard dressing | Arm Label: PICO Dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: PREVENA Negative pressure wound versus standard dressing | Arm Label: PREVENA Dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Smith & Nephew PICO Negative wound pressure versus standard dresing | Intervention Type: DEVICE; Name: Smith & Nephew PICO Negative wound pressure versus standard dresing; Assigned to Arm(s): PREVENA Dressing, Simple dressing | Intervention Type: DEVICE; Name: PREVENA Negative pressure wound versus standard dressing; Assigned to Arm(s): PICO Dressing, Simple dressing
D: Arm Label: Vacuum-assisted closure (VAC); Type: EXPERIMENTAL; Interventions: Device: Vacuum-assisted closure | Arm Label: Standard sterile dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard sterile dressing | Intervention Type: DEVICE; Name: Vacuum-assisted closure; Assigned to Arm(s): Vacuum-assisted closure (VAC) | Intervention Type: DEVICE; Name: Standard sterile dressing; Assigned to Arm(s): Standard sterile dressing

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) for treating patients with mild to moderate Ulcerative Colitis (UC). Even with the expanding choices of medication for UC, physicians and patients are still in search of highly effective and safe medications with minimal side effects. FMT has been approved for the treatment of a bacterial infection called Clostridium difficile. In this setting, FMT has been proven to be an effective and safe alternative therapy with zero reported serious adverse events from patients that have had this treatment.

The providers that are conducting this study hypothesize that delivering microbes from a healthy human gut can help treat the damages caused by UC. This is done by "transplanting" fecal material, which contains a highly complex and dense community of healthy microbes, including bacteria, fungi and viruses. This collection of microbes is referred to as a microbiome. Preliminary studies suggest that alteration of the microbiome can help treat UC.


Options:
A: Arm Label: SER-109; Type: EXPERIMENTAL; Interventions: Biological: SER-109 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: SER-109; Assigned to Arm(s): SER-109 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplant | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplant; Assigned to Arm(s): Treatment | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control
C: Arm Label: Fecal Microbiota Enema; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Enema | Arm Label: Normal Saline Enema; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal Saline Enema | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Enema; Assigned to Arm(s): Fecal Microbiota Enema | Intervention Type: BIOLOGICAL; Name: Normal Saline Enema; Assigned to Arm(s): Normal Saline Enema
D: Arm Label: MICROBIOTA; Type: EXPERIMENTAL; Interventions: Biological: MICROBIOTA | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Biological: PLACEBO | Intervention Type: BIOLOGICAL; Name: MICROBIOTA; Assigned to Arm(s): MICROBIOTA | Intervention Type: BIOLOGICAL; Name: PLACEBO; Assigned to Arm(s): PLACEBO

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Problem-solving Based Bibliotherapy Program for Family Caregivers of People With Psychotic Disorders
Brief Summary: This proposed randomized controlled trial will test the effectiveness of a problem-solving based bibliotherapy program (PSBBP) for Chinese family caregivers in psychotic disorders (not more than 5 years onset). A repeated-measures, three-group design will be used to evaluate and compare the effects between two treatment groups(PSBBP and psycho-education group) and routine outpatient service and family support (control group) for 198 randomly selected family caregivers of outpatients with psychotic disorders over a 24-month follow-up.

Before the 3-arm trial to be conducted, a pilot parallel-group randomised controlled trial with a similar study design to the later three-arm randomised controlled trial (Phase 2) will be conducted at one psychiatric outpatient clinic in Hong Kong. Receiving an additional funding from local government, another pilot two-arm trial will also be conducted for family caregivers of people with first-episode psychosis in the community to support and inform the 3-arm randomised controlled trial.


Options:
A: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: glycine | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): 1
C: Arm Label: Self-learning program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-learning program | Arm Label: Psycho-education (in Phase 2); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psycho-education program (in Phase 2) | Arm Label: Routine community care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-learning program; Assigned to Arm(s): Self-learning program | Intervention Type: BEHAVIORAL; Name: Psycho-education program (in Phase 2); Assigned to Arm(s): Psycho-education (in Phase 2)
D: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nitrous Oxide for Pain Management of Intrauterine Device Insertion
Brief Summary: The purpose of this study is to determine whether Nitrous Oxide is effective in achieving pain control and satisfaction among nulliparous women getting the intrauterine device (IUD).


Options:
A: Arm Label: Oxygen (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Oxygen | Arm Label: Nitrous Oxide (NO); Type: EXPERIMENTAL; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Nitrous oxide | Intervention Type: PROCEDURE; Name: IUD insertion; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Povidone-Iodine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: OTHER; Name: Oxygen; Assigned to Arm(s): Oxygen (Placebo) | Intervention Type: OTHER; Name: Nitrous oxide; Assigned to Arm(s): Nitrous Oxide (NO)
B: Arm Label: Placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo Gel | Arm Label: Nitroprusside Gel; Type: EXPERIMENTAL; Interventions: Procedure: Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Nitroprusside Gel; Assigned to Arm(s): Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Placebo Gel; Assigned to Arm(s): Placebo gel
C: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Drug: 2% lidocaine gel | Intervention Type: DRUG; Name: 2% lidocaine gel; Assigned to Arm(s): Study Group | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): Control Group
D: Arm Label: Group 1: Intravaginal 2% lidocaine gel; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: Group 2: Intravaginal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group 1: Intravaginal 2% lidocaine gel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Intravaginal placebo gel

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and a second allele with a CFTR mutation predicted to have residual function.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
B: Arm Label: VX-661/Ivacaftor combination; Type: EXPERIMENTAL; Interventions: Drug: VX-661/Ivacaftor, Drug: Ivacaftor, Drug: Placebo matched to Ivacaftor | Arm Label: Ivacaftor monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo matched to VX-661/ ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to VX-661/ ivacaftor, Drug: Placebo matched to Ivacaftor | Intervention Type: DRUG; Name: VX-661/Ivacaftor; Assigned to Arm(s): VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Placebo matched to VX-661/ ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, Placebo | Intervention Type: DRUG; Name: Placebo matched to Ivacaftor; Assigned to Arm(s): Placebo, VX-661/Ivacaftor combination
C: Arm Label: Group 1 - 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 2 - 100 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 3 - 200 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 4 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: N91115 | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): Group 1 - 50 mg, Group 2 - 100 mg, Group 3 - 200 mg, Group 4 - Placebo
D: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
Brief Summary: The REDUCE HTN: REINFORCE study is being conducted to determine whether the Vessix Reduce™ Catheter and Vessix™ Generator for the treatment of uncontrolled hypertension (off-treatment office systolic blood pressure ≥150 mmHg and ≤180 mmHg) shows acceptable performance at 8 weeks when compared to a masked procedure (renal angiogram).


Options:
A: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal denervation and optimized medication regimen | Arm Label: optimized medication regimen; Type: OTHER; Interventions: Procedure: optimized medication regimen | Intervention Type: PROCEDURE; Name: renal denervation and optimized medication regimen; Assigned to Arm(s): Renal denervation | Intervention Type: PROCEDURE; Name: optimized medication regimen; Assigned to Arm(s): optimized medication regimen
B: Arm Label: Renal Denervation plus Medications; Type: EXPERIMENTAL; Interventions: Device: Radiofrequency ablation catheter, Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Arm Label: Medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Intervention Type: DEVICE; Name: Radiofrequency ablation catheter; Assigned to Arm(s): Renal Denervation plus Medications | Intervention Type: DRUG; Name: Amlodipine, losartan potassium and hydrochlorothiazide; Assigned to Arm(s): Medications, Renal Denervation plus Medications
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation (Symplicity® Renal Denervation System) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Renal Denervation (Symplicity® Renal Denervation System); Assigned to Arm(s): Renal Denervation
D: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation (Vessix) | Arm Label: Masked Procedure; Type: SHAM_COMPARATOR; Interventions: Device: Renal Angiography | Intervention Type: DEVICE; Name: Renal Denervation (Vessix); Assigned to Arm(s): Renal Denervation | Intervention Type: DEVICE; Name: Renal Angiography; Assigned to Arm(s): Masked Procedure

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a Dietary Supplement on Endothelial Function in Volunteers With Light to Moderate Hypertension - a Randomised, Double-blind, Placebo Controlled Cross-over Study
Brief Summary: The effect of a combination product (Verum ) with L-arginine, Pycnogenol, vitamin K2, R-(+)-alpha-lipoic acid and vitamins B6, B12 and folic acid is investigated in a double blind placebo-controlled cross-over study. Volunteers with hypertension and hyperhomocysteinemia are randomly assigned to the dietary supplement or placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pycnogenol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pycnogenol | Intervention Type: DRUG; Name: Pycnogenol; Assigned to Arm(s): Pycnogenol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: supplement - no retinopathy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: multi-component nutritional supplement capsules | Arm Label: placebo - no retinopathy; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: multi-component dietary supplement | Arm Label: supplement - retinopathy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: multi-component nutritional supplement capsules | Arm Label: placebo - retinopathy; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: multi-component dietary supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: multi-component nutritional supplement capsules; Assigned to Arm(s): supplement - no retinopathy, supplement - retinopathy | Intervention Type: DIETARY_SUPPLEMENT; Name: multi-component dietary supplement; Assigned to Arm(s): placebo - no retinopathy, placebo - retinopathy
C: Arm Label: Verum; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Verum | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Verum; Assigned to Arm(s): Verum | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pine Bark Extract (Flavangenol®) | Arm Label: Pine Bark Extract; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pine Bark Extract (Flavangenol®) | Intervention Type: DRUG; Name: Pine Bark Extract (Flavangenol®); Assigned to Arm(s): Pine Bark Extract, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Late LTP-like Plasticity Effects of tDCS in Subacute Stroke Patients
Brief Summary: Rationale: About 80% of stroke patients suffer motor impairments, but current therapies have limited effects on motor recovery. Therefore, investigating new potential therapeutic approaches is crucial. Transcranial Direct Current Stimulation (tDCS) is a form of non-invasive electrical stimulation where a weak current is applied through electrodes over the scalp. This stimulation is known to (1) induce changes in neuronal excitability -which can last up to one day with late LTP-like plasticity protocols in a polarity and site-specific manner, and (2) facilitate motor learning and stroke recovery. So far, several pilot studies have reported beneficial results from tDCS in both subacute and chronic stroke patients, but it's still unclear how tDCS should be repeated over multiple days to optimally enhance recovery and training effects. Using a late LTP-like plasticity protocol could increase effectiveness of standard clinical care rehabilitation sessions and thus enhance the effects of rehabilitation. Therefore, the investigators want to investigate how late LTP-like plasticity tDCS affects rehabilitation in subacute stroke patients. The outcome of this study can provide important guidelines on effective motor therapy during stroke rehabilitation.

Objective: Identify the effect of late LTP-like plasticity on motor rehabilitation during the subacute phase after stroke.

Study design: Double-blinded, randomized between-subjects trials. Study population: Subacute stroke patients. Main study parameters/endpoints: The primary outcome measure is the upper limb motor function during the subacute phase after stroke.


Options:
A: Arm Label: Real stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS (ELDITH) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: tDCS (ELDITH) | Intervention Type: DEVICE; Name: tDCS (ELDITH); Assigned to Arm(s): Real stimulation, Sham
B: Arm Label: tDCS and occupational therapy; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: Sham and occupational therapy; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): tDCS and occupational therapy | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham and occupational therapy
C: Arm Label: Sham; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham, tDCS
D: Arm Label: Transcranial direct current stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial direct current stimulation (tDCS) | Arm Label: ARM 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Transcranial direct current stimulation (tDCS); Assigned to Arm(s): Transcranial direct current stimulation | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): ARM 2

Answer: C